NEW YORK (GenomeWeb News) – Genome engineering firm Cellectis on Thursday reported that its total operating revenues slipped 8 percent year over year during the first half of 2013.

For the first six months of the year, the Paris-based firm brought in €6.9 million ($9.4 million) in operating revenues, compared to €7.5 million during the first half of 2012. Operating revenues for the recently completed period comprised €2.8 million in sales, down from €3.1 million a year ago, and €4.1 million in other operating revenues, down from €4.4 million a year ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.